We are live on ! Find out more
HC

Hampstead Capital Portfolio holdings

AUM $55.8M
1-Year Est. Return 2.76%
This Fund
S&P 500
This Quarter Est. Return
+3.11%
1 Year Est. Return
+2.76%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
-$663K
Cap. Flow
-$3.13M
Cap. Flow %
-3.1%
Top 10 Hldgs %
45.49%
Holding
34
New
2
Increased
10
Reduced
10
Closed
2

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$3.18M
2
AIG icon
American International
AIG
+$1.62M
3
PXD
Pioneer Natural Resource Co.
PXD
+$1.44M
4
INVX
Innovex International
INVX
+$870K
5
EXC icon
Exelon
EXC
+$750K

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$3.65M
2
PFE icon
Pfizer
PFE
+$3.12M
3
GM icon
General Motors
GM
+$1.21M
4
MOS icon
The Mosaic Company
MOS
+$1.08M
5
DXC icon
DXC Technology
DXC
+$725K

Sector Composition

Rank Sector Weight
1 Healthcare 19.28%
2 Communication Services 15.82%
3 Energy 15.73%
4 Utilities 11.49%
5 Technology 9.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GG
26
DELISTED
Goldcorp Inc
GG
$2M 1.98%
154,000
– –
RTX icon
27
RTX Corp
RTX
$290B
$1.74M 1.72%
23,835
– –
MOS icon
28
The Mosaic Company
MOS
$7.03B
$1.29M 1.28%
60,000
-50,000
-45% -$1.08M
INVX
29
Innovex International
INVX
$1.96B
$883K 0.87%
+20,000
New +$870K
CTRA
30
DELISTED
Coterra Energy
CTRA
$669K 0.66%
25,000
-25,000
-50% -$635K
XPRO icon
31
Expro Ltd
XPRO
$1.79B
$618K 0.61%
13,333
– –
AVP
32
DELISTED
Avon Products, Inc.
AVP
$350K 0.35%
150,000
– –
DXC icon
33
DXC Technology
DXC
$1.82B
– –
-10,923
Closed -$725K
TEVA icon
34
Teva Pharmaceuticals
TEVA
$40.8B
– –
-110,000
Closed -$3.65M
1
2

Similar funds

CCP
Centaur Capital Partners Southlake, Texas $54.1M AUM 12.4% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CLA
Cranberry Lake Advisors Houston, Texas $50.6M AUM 5.12% 1-Year Est. Return
EIC
ENA Investment Capital London, United Kingdom $61.8M AUM
SF
Schooner Foundation Boston, Massachusetts $49.6M AUM 9.4% 1-Year Est. Return
DIV
DCM International V Menlo Park, California $47.8M AUM 19.52% 1-Year Est. Return
MGPI
Maveron General Partner III Seattle, Washington $46.7M AUM 35.29% 1-Year Est. Return
BOIA
Bush ODonnell Investment Advisors St Louis, Missouri $65.2M AUM 13.39% 1-Year Est. Return

Hampstead Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Hampstead Capital held 34 positions worth $101M, down 0.65% from $102M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Hampstead Capital withdrew a net $3.13M in Q3 2017, closing 2 positions and reducing 10 holdings. Its most notable exit was Teva Pharmaceuticals, an estimated $3.65M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 24% a quarter earlier, followed by Communication Services and Energy.

Against the trend, Hampstead Capital opened a new position in Merck worth $3.2M.

  • Hampstead Capital's largest Q3 2017 buy was Merck: 52,400 shares worth $3.2M.
  • Hampstead Capital added most to American International in Q3 2017, an estimated $1.62M increase.
  • Hampstead Capital's biggest Q3 2017 reduction was Pfizer, cutting an estimated $3.12M.
  • Hampstead Capital fully exited Teva Pharmaceuticals in Q3 2017, selling an estimated $3.65M.
  • Hampstead Capital's ten largest holdings make up 45% of its $101M portfolio in Q3 2017.
  • Hampstead Capital opened 2 new positions and closed 2 in Q3 2017.
  • Hampstead Capital's portfolio value fell 0.65% quarter-over-quarter to $101M.

Based on Hampstead Capital's 13F filing for Q3 2017, filed 15 Nov 2017.